Shiro Akinaga
Directeur Général chez NANO MRNA CO.,LTD.
Fortune : 90 589 $ au 30/04/2024
Profil
Shiro Akinaga is currently the President, CEO & Representative Director at NANO MRNA Co., Ltd.
since 2022.
He is also the Chairman & Chief Executive Officer at AccuRna, Inc. since 2017.
Previously, he worked at Kyowa Kirin Co., Ltd.
as an Executive Officer & Manager-Overseas Development.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
NANO MRNA CO.,LTD.
0,11% | 31/03/2023 | 78 760 ( 0,11% ) | 90 589 $ | 30/04/2024 |
Postes actifs de Shiro Akinaga
| Sociétés | Poste | Début |
|---|---|---|
| NANO MRNA CO.,LTD. | Directeur Général | 01/12/2022 |
AccuRna, Inc.
 AccuRna, Inc. BiotechnologyHealth Technology AccuRna, Inc. researches and develops nucleic acid-based drugs using drug delivery system technologies. The company was founded on December 18, 2015 and is headquartered in Tokyo, Japan. | Directeur Général | 01/03/2017 |
Anciens postes connus de Shiro Akinaga
| Sociétés | Poste | Fin |
|---|---|---|
| KYOWA KIRIN CO. LTD. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| KYOWA KIRIN CO. LTD. | Health Technology |
| NANO MRNA CO.,LTD. | Health Technology |
| Entreprise privées | 1 |
|---|---|
AccuRna, Inc.
AccuRna, Inc. BiotechnologyHealth Technology AccuRna, Inc. researches and develops nucleic acid-based drugs using drug delivery system technologies. The company was founded on December 18, 2015 and is headquartered in Tokyo, Japan. | Health Technology |